Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Promising treatments under investigation in Waldenström’s macroglobulinemia

Jorge Castillo • 15 Jun 2022
EHA 2022
Rare Diseases Waldenström’s Macroglobulinemia Acalabrutinib Antibodies Bendamustine CAR-T CLR 131 Loncastuximab tesirine Nemtabrutinib Pirtobrutinib Rituximab Venetoclax Zanubrutinib

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on promising therapies that are being developed for the treatment of Waldenström’s macroglobulinemia (WM), including fixed-duration triplet regimens, BTK inhibitor combination strategies, CLR 131, loncastuximab tesirine, and CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consulting fees and/or research funds from Abbvie, AstraZeneca, BeiGene, Cellectar, Janssen, Pharmacyclics, Roche, TG Therapeutics.

More from Jorge Castillo

Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
3:13
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
Jorge Castillo • 7 Dec 2024
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
2:25
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
Jorge Castillo • 7 Dec 2024

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals